share_log

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Benzinga ·  May 8 09:33

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment